# ClinicalTrials.gov record NCT05168774

> PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct05168774-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05168774-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05168774-elamipretide-v1.json
- Content SHA-256: `70420618a7b50074a1e039d48008ff6b2e7e9270bad545c7dc27ffc64fec3e8a`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05168774 ([`ctg-observation-nct05168774-2025-12-12-b710dca893fb`](#source-ctg-observation-nct05168774-2025-12-12-b710dca893fb))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct05168774-2025-12-12-b710dca893fb`](#source-ctg-observation-nct05168774-2025-12-12-b710dca893fb))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct05168774-2025-12-12-b710dca893fb`](#source-ctg-observation-nct05168774-2025-12-12-b710dca893fb))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05168774-2025-12-12-b710dca893fb`](#source-ctg-observation-nct05168774-2025-12-12-b710dca893fb))

## Sources

<a id="source-ctg-observation-nct05168774-2025-12-12-b710dca893fb"></a>
- **ClinicalTrials.gov record NCT05168774 · retained source version 2025-12-12:b710dca893fb6d67975a19f6658d9aa6bee1ff37bd95c383b5015319903d4c0e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05168774) (`ctg-observation-nct05168774-2025-12-12-b710dca893fb`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05168774." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05168774-elamipretide-v1.json SHA-256: 70420618a7b50074a1e039d48008ff6b2e7e9270bad545c7dc27ffc64fec3e8a.